Skip to Content
Thermo Fisher Scientific, which sells equipment, software, and services for scientific research, had a stellar 2020, lifted by huge demand for its products, such as PCR tests, during the pandemic. The lab supplier collected $6.6 billion in revenue during the year from sales of instruments and other products to more than 200 customers trying to develop COVID-19 vaccines and treatments. Overall revenue rose 26% to $32 billion, compared with the prior year, while profits soared 73% to $6.4 billion. Even with the COVID vaccine rush behind them, the company is thinking big with its $17.4 billion acquisition of contract research business PPD, which it announced in April.
Lists ranking Thermo Fisher Scientific
RANK95
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list
RANK498
Global 500 - 2020This year's Global 500 generated $33.3 trillion in...READ MOREview in list